Pfizer will name three. Goettler will also get a seat, for a total of 13 members. Mylan executives met in New York last week to discuss the accord, and no one else is likely to bid for the company, according to a person familiar with the transaction. Mylan, whose shares have fallen almost 50% in the past year, has a market value of $9.5 billion. Pfizer is up 12% in the same period and is worth $240 billion. The business would be based in the U.S., removing the Dutch governance structure that has frustrated some Mylan investors and is essentially a takeover defense. Earlier, Mylan reported earnings that beat analyst estimates. Second-quarter adjusted earnings were $1.03 a share, topping the 95 cents average of Wall Street's estimates compiled by Bloomberg. The company reaffirmed its 2019 forecast of adjusted earnings of $3.80 to $4.80 a share and revenue of $11.5 billion to $12.5 billion. Pfizer posted second-quarter adjusted earnings per share of 80 cents, beating the average Wall Street estimate of 75 cents.